FDA Rejects UniQure's AMT-130 Gene Therapy Data for Huntington's, Demands New Sham-Controlled Trial on March 06, 2026 AMT-130 gene therapy Huntington 's disease Phase 1/2 data sham-controlled trial uniQure United States Food and Drug Administration +